Format

Send to

Choose Destination
Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243.

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

[Article in English, Norwegian]

Abstract

BACKGROUND:

High-dose therapy with autologous stem cell support (HDT) has been a treatment option for lymphomas in Norway for 25 years. The purpose of the article was to describe the use of the therapy for lymphomas for the country as a whole and by health region, and to reveal the overall survival rate.

METHOD:

All lymphoma patients ≥ 18 years who received HDT in Norway in the period 1987-2008 are included. Patients, diagnostics and treatment are identified for each hospital. Data for the population base have been retrieved from Statistics Norway.

RESULTS:

Altogether 726 lymphoma patients received HDT in Norway in the period 1987-2008, with an annual average of 0.72 per 100,000 inhabitants. The annual number of treatments increased until 2004 and has since been stable. The average number of treatments per 100,000 inhabitants per year was 0.94 for Northern Norway Health Region, 0.80 for South-Eastern Norway Health Region, 0.58 for Central Norway Health Region and 0.55 for Western Norway Health Region. Early mortality (death within 100 days) was 6%. Ten-year overall survival was 55% (95% CI 51-59%), and Hodgkin's lymphoma had the best survival of the lymphoma groups (p = 0.01).

INTERPRETATION:

The annual number of HDT increased gradually until 2004. The use of the treatment varied according to the patients' place of residence at the time of diagnosis, and was most frequently used for patients belonging to Northern Norway Health Region. More than half of the lymphoma patients are alive ten years after the treatment.

PMID:
24005706
DOI:
10.4045/tidsskr.13.0243
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Norwegian Medical Association
Loading ...
Support Center